Introduction The relationship of venous thromboembolism (VTE) with platelet reactivity is
unclear. Platelet function plays a key role in arterial thrombosis. Evidence suggests …

Aims Observational studies indicate that statins reduce the risk of recurrent venous
thrombosis (VT). However, trials have not been performed and the mechanism is unknown …

Background Extracellular vesicles (EVs), shed in response to cell activation, stress, or injury,
are increased in the blood of patients with cardiovascular disease. EVs are characterized by …

Essentials• Statins, especially rosuvastatin, may reduce venous thrombosis risk, but the
mechanism is unclear.• We performed a randomized trial investigating the effect of …

Background and aims High plasma LDL-cholesterol (LDL-C) and platelet responses have
major pathogenic roles in atherothrombosis. Thus, statins and anti-platelet drugs constitute …

Although excessive amounts of certain clotting factors and lack of inhibitors have been
associated with increased risk of venous thromboembolism (VTE)[1], activation of …

This dataset includes all reports and summaries of raw data supporting the results presented
in the paper'Extracellular vesicles from patients with coronary artery disease (CAD) …

Introduction: Thrombin, the enzyme which converts fibrinogen into a fibrin clot, is produced
by the prothrombinase complex, composed of factor Xa (FXa) and factor Va (FVa). Down …

Venous thromboembolism (VTE) is a multicausal disease, often involving acquired or
environmental risk factors, as well as a genetic predisposition [1]. Long-term anticoagulant …